Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

PSNL vs NDRA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PSNL Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 5–3 Matrix Metrics)

PSNL Overall Winner 6-Pillar Tally: PSNL 4 – 1 NDRA (1 Tie) Matrix Metrics: PSNL 5 – 3 NDRA

As of Nov 16, 2026, Personalis, Inc. (PSNL) is the stronger overall head-to-head candidate over ENDRA Life Sciences Inc. (NDRA) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). PSNL carries a Unified Composite Score of 33.0/100 (SELL) at $14.80 (N/M Forward P/E, -156.7% operating margin), whereas NDRA carries 44.7/100 (HOLD) at $4.42 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While NDRA currently prints a higher short-term Unified Composite Score (44.7/100 HOLD vs. PSNL 33.0/100 SELL), PSNL captures the overall institutional head-to-head verdict (5–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-156.7% vs. 0.0% operating margin) and revenue trajectory (+76.6% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: PSNL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0); meanwhile NDRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PSNL vs NDRA
PSNL NASDAQ Head-to-Head Winner
Personalis, Inc. Common Stock
Services-Medical Laboratories
$14.80
-5.79% 1D
Market Cap $1.7B
TTM Revenue $81M
Forward P/E N/M
Beta / 30D Vol 1.86β · 21% Vol
Unified Composite Score
33.0 / 100 SELL
Tech 9.0 Fund 48.0 Flow 58.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -0.5%), weak momentum, RSI 28
RSI-14: 28.0 · SMA20: $15.80 · SMA50: $16.03
NDRA NASDAQ
ENDRA Life Sciences Inc. Common Stock
Electromedical & Electrotherapeutic Apparatus
$4.42
+0.23% 1D
Market Cap $6.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.71β · 48% Vol
Unified Composite Score
44.7 / 100 HOLD
Tech 35.0 Fund 46.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -1.3%), weak momentum, RSI 37
RSI-14: 36.7 · SMA20: $4.75 · SMA50: $5.32

6-Pillar Scorecard Institutional Category Breakdown (PSNL 4 – 1 NDRA)

Columns: Metric · PSNL · NDRA
1. Valuation Multiples PSNL
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 20.3x N/M
2. Growth & Scale PSNL
Revenue Growth (YoY) +76.6% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $81M N/A
Market Cap $1.7B $6.6M
3. Profitability & Quality NDRA
Gross Margin 16.7% N/A
Operating Margin -156.7% 0.0%
Net Profit Margin -147.7% 0.0%
Return on Equity (ROE) -62.1% -152.0%
4. Balance Sheet & Cash Flow PSNL
Cash Generation (TTM) -$108M -$8.0M
Cash Flow Margin N/A N/A
Net Cash / Leverage $61M Net Cash $104,744 Net Debt (0.26x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PSNL
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 35.2% (2nd %ile) N/A (N/A)
Put/Call OI Skew 0.02x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Diagnostics & Research Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PSNL (5) vs NDRA (3)
Institutional Metric PSNL NDRA Criterion Row Edge
Market Capitalization
Scale
$1.7B $6.6M Larger Scale PSNL
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+76.6% +0.0% Higher Growth PSNL
Operating Margin (TTM)
Profitability
-156.7% 0.0% Higher Margin NDRA
Net Profit Margin
Profitability
-147.7% 0.0% Higher Margin NDRA
Return on Equity (ROE)
Capital Efficiency
-62.1% -152.0% Higher ROE PSNL
52-Week Range Position
Momentum
71% ($5–$19) 37% ($3–$7) Stronger Trend PSNL
Beta / 30D Volatility
Risk Regime
1.86β · 21% Vol 0.71β · 48% Vol Lower Realized Risk PSNL
Unified Institutional Score
Composite Signal
33.0 / 100 (SELL) 44.7 / 100 (HOLD) Higher Composite NDRA
Trailing 12M Revenue (USD)
Operating Scale
$81M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
16.7% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 20.3x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$108M ($61M Net Cash) -$8.0M ($104,744 Net Debt (0.26x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PSNL +1.32 pp
PSNL: -5.43% · NDRA: -6.75%
3M Horizon PSNL +8.4 pp
PSNL: +6.4% · NDRA: -2.0%
6M Horizon PSNL +138.54 pp
PSNL: +120.24% · NDRA: -18.3%
1Y Horizon PSNL +127.46 pp
PSNL: +94.74% · NDRA: -32.72%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period PSNL Revenue NDRA Revenue PSNL Op. Margin NDRA Op. Margin Margin Leader
FY2018 $40M $0M -36.5% -146080.5% PSNL
FY2019 $70M N/A -34.4% N/A PSNL
FY2020 $80M N/A -53.6% N/A PSNL
FY2021 $90M N/A -76.4% N/A PSNL
FY2022 $70M N/A -177.6% N/A PSNL
FY2023 $70M N/A -149.6% N/A PSNL
FY2024 $80M N/A -80.7% N/A PSNL
FY2025 $70M N/A -126.4% N/A PSNL

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PSNL CONSOLIDATION
87d in phase · OBV NEUTRAL
Current IV 35.2%
IV Percentile 2nd %ile
Put/Call OI Skew 0.02x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact PSNL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NDRA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NDRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PSNL Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $1.7B market capitalization and -156.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
NDRA Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $6.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PSNL vs NDRA Key Questions & Quantitative Answers

As of Nov 16, 2026, Personalis, Inc. (PSNL) is the stronger overall head-to-head candidate over ENDRA Life Sciences Inc. (NDRA) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). PSNL carries a Unified Composite Score of 33.0/100 (SELL) at $14.80 (N/M Forward P/E, -156.7% operating margin), whereas NDRA carries 44.7/100 (HOLD) at $4.42 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While NDRA currently prints a higher short-term Unified Composite Score (44.7/100 HOLD vs. PSNL 33.0/100 SELL), PSNL captures the overall institutional head-to-head verdict (5–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-156.7% vs. 0.0% operating margin) and revenue trajectory (+76.6% vs. +0.0% YoY). Technical & Structure Timing Caution: PSNL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0); meanwhile NDRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PSNL leads the Growth & Scale pillar: PSNL posts +76.6% YoY revenue growth and +0.0% YoY earnings growth on $81M TTM revenue (16.7% gross margin, -156.7% operating margin), compared with NDRA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), PSNL cumulative revenue shifted +75.0% while NDRA shifted N/A. In operating R&D and SG&A reinvestment, PSNL deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NDRA.

PSNL screens cheaper on headline valuation multiples. PSNL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 20.3x EV/Revenue (unreported FCF margin), whereas NDRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PSNL (-62.1% ROE) versus NDRA (-152.0% ROE) capital efficiency.

In options market volatility and institutional positioning, PSNL carries 35.2% implied volatility (2nd %ile, Compressed (<25th %ile)), a 0.02x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.86β · 21% Vol realized risk). By comparison, NDRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.71β · 48% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.